NXEN — Nexien Biopharma Income Statement
0.000.00%
Last trade - 00:00- $0.69m
- $0.96m
Annual income statement for Nexien Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.67 | 1.84 | 0.564 | 0.283 | 0.156 |
| Operating Profit | -2.67 | -1.84 | -0.564 | -0.283 | -0.156 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.67 | -1.86 | -0.626 | -0.362 | -0.239 |
| Net Income After Taxes | -2.67 | -1.86 | -0.626 | -0.362 | -0.239 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.67 | -1.86 | -0.626 | -0.362 | -0.239 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.67 | -1.86 | -0.626 | -0.362 | -0.239 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.049 | -0.034 | -0.011 | -0.006 | -0.004 |